Abstract
What We're Reading| May 03 2023 A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors Author & Article Information Online ISSN: 2326-6074 Print ISSN: 2326-6066 ©2023 American Association for Cancer Research2023American Association for Cancer Research Cancer Immunol Res (2023) 11 (5): 557. https://doi.org/10.1158/2326-6066.CIR-11-5-WWR Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record May 3 2023 Citation A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors. Cancer Immunol Res 1 May 2023; 11 (5): 557. https://doi.org/10.1158/2326-6066.CIR-11-5-WWR Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Polyclonal neoantigen-specific T-cell responses associate with anti–PD-1 benefit (from Alex Ritter, Jennifer Lippincott Schwartz and Gillian Griffiths via NIH Flickr) To better understand differences in the immune response in patients with metastatic melanoma who do and do not have a clinical response to anti–PD-1 therapy, Puig-Saus et al. generated neoantigen-specific T cells from 11 patients using personalized neoantigen peptide–HLA libraries. Responding and nonresponding patients had neoantigen-specific CD8+ T cells in peripheral blood and tumor that recognized a limited number of mutations, but the CD8+ T cells from those who responded to therapy were more polyclonal, with multiple neoantigen-specific T-cell receptor clonotypes for the mutations, and were detected longitudinally, highlighting important immune characteristics of a successful clinical response to anti–PD-1 therapy. Puig-Saus C, …, Ribas A. Nature 2023 March 8;615:697–704. Neutrophils have a key role in tumor control following immunotherapy (from SVG) Neutrophils can have both pro- and... You do not currently have access to this content.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
